Skip to main content
HR 5463 117th Congress House

Drug Pricing Transparency and Accountability Act

Official title: To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.

Introduced: September 30, 2021 See on congress.gov
Health Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesGovernment information and archives
More subjectsShow fewer subjects
Government studies and investigationsHealth facilities and institutionsHealth information and medical recordsHome and outpatient careHospital careMedicaidMedicarePrescription drugsPublic contracts and procurementPublic-private cooperationState and local government operations
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 1, 2021
Referred to the Subcommittee on Health.
Sep 30, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 30, 2021
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 1, 2021

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.

 Related & companion bills 1
  • HR 198 Reintroduced Bill Drug Pricing Transparency and Accountability Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5463: Drug Pricing Transparency and Accountability Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-5463/
MLA
"H.R. 5463: Drug Pricing Transparency and Accountability Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-5463/.
Bluebook (legal)
H.R. 5463, 117th Cong. (2026), https://openamerica.io/bill/117-HR-5463/.
Markdown link
[H.R. 5463: Drug Pricing Transparency and Accountability Act](https://openamerica.io/bill/117-HR-5463/)
Report a problem